Algonomics
Innovative bioinformatics for rationally designed immunotherapeutics through advanced protein and peptide interaction platforms.
Innovative bioinformatics for rationally designed immunotherapeutics through advanced protein and peptide interaction platforms.
AlgoNomics is a Belgium-based biotechnology company founded in 1999. The company specializes in structural bioinformatics services for the development of precisely designed therapeutics within the field of immunotherapy. AlgoNomics is known for its proprietary platform dedicated to structure-based protein and peptide design, which includes innovative tools for exploring protein-protein and protein-peptide interactions. Their flagship product, the Epibase® platform, stands out for its capability to identify T-cell epitopes across diverse population groups and is instrumental in the discovery of vaccines and therapeutic proteins. The latest funding round took place on 20 June 2007, with a €1.50M Venture Round investment from VIB, Gemma Frisius Fund, Baekeland Funds, and TrustCapital. This investment signifies the market's confidence in AlgoNomics' innovative bioinformatics approach and its potential to drive advancements in immunotherapeutics. The company's mission, as reflected in its slogan, is to leverage advanced protein and peptide interaction platforms to revolutionize the field of immunotherapy. With its strong investor backing and cutting-edge technology, AlgoNomics is well-positioned to make significant contributions to the biotechnology industry.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | €1.50M | 4 |
|
20 Jun 2007 |
No recent news or press coverage available for Algonomics.
We care about your data, and we'd love to use cookies make your experience better.
